The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Nov. 22, 2022
Filed:
Jun. 20, 2019
Merck Sharp & Dohme Llc, Rahway, NJ (US);
Ra Pharmaceuticals, Inc., Cambridge, MA (US);
Alonso Ricardo, Cambridge, MA (US);
Thomas Joseph Tucker, North Wales, PA (US);
Nicolas Cedric Boyer, Somerville, MA (US);
Ketki Ashok Dhamnaskar, Cambridge, MA (US);
Zhong Ma, Lexington, MA (US);
Angela Dawn Kerekes, Plainfield, MA (US);
Chengwei Wu, Ambler, PA (US);
Sookhee Nicole Ha, Warren, NJ (US);
Hyewon Youm, Berkeley Heights, NJ (US);
Elisabetta Bianchi, Rome, IT;
Danila Branca, Pomezia, IT;
Raffaele Ingenito, Pomezia, IT;
Willy Costantini, Pomezia, IT;
Aurash Shahripour, Gaithersburg, MD (US);
Yusheng Xiong, Plainsboro, NJ (US);
Merck Sharp & Dohme LLC, Rahway, NJ (US);
Ra Pharmaceuticals, Inc., Cambridge, MA (US);
Abstract
Provided herein are cyclic polypeptide compounds that can, e.g., bind specifically to human proprotein convertase subtilisin/kexin type 9 (PCSK9) and optionally also inhibit interaction between human PCSK9 and human low density lipoprotein receptor (LDLR), and pharmaceutical compositions comprising one or more of these compounds. Also provided are methods of reducing LDL cholesterol level in a subject in need thereof that include administering to the subject one or more of the cyclic polypeptide compounds or a pharmaceutical composition provided herein.